Ablynx books success with arthritis drug study
BRUSSELS Feb 13 (Reuters) - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
"We are now investigating the various possibilities through which we can progress the development of ALX-0061, including discussions with potential partners and other paths which will allow us to maximise the value of this asset," Chief Executive Edwin Moses said in a statement on Wednesday.
Ablynx had carried out the study on 37 patients over the course of 24 weeks and said the drug was well-tolerated and showed positive results. (Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Suspect in Pennsylvania police ambush captured after seven-week manhunt |
- Global shares jump, yen slumps as BOJ cranks up stimulus
- Oil price declines have small-cap shale investors scrambling
- Special Report: Tsunami evacuees caught in $30 billion Japan money trap